Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
Recruiting
N/A
Interventional Study
Type 2 Diabetes Mellitus
Susceptibility, Genetic
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 25 – 70
- Sex
- Any
- Study type
- Interventional
- Purpose
- Prevention
- Participants needed
- 300 (estimated)
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This is a retrospective cohort study of patients with T2DM who were treated with exenatide twice daily as a part of their diabetes care for at least 12 months. The objective of this study is to investigate the influence of T2DM susceptibility gene polymorphisms (NOS1AP, KCNQ1, TCF7L2, WSF1, GLP-1R, etc.) on the efficacy of GLP-1 RA (exenatide, liraglutide, etc.), to identify the variables that can…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. a diagnosis of T2DM
2. a body mass index (BMI) of 20-35 kg/m2
3. an HbA1c of 7.0%-12%, an age of 25-70 years
4. required data available at baseline and 6 months after GLP-1RA therapy.
Exclusion Criteria:
1. Patients with serious diseases such as acute myocardial infarction,…
Contacts